KYMR vs. NVS: Kymera Therapeutics vs. Novartis Stock Comparison

Company Profile

Kymera Therapeutics (KYMR) and Novartis (NVS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but KYMR is classified in Biotechnology while NVS is classified in Pharmaceuticals.

Novartis (NVS) has more than two decades of public-market history since November 7, 1996, whereas Kymera Therapeutics (KYMR) listed on August 21, 2020 and has a much shorter record to draw on.

Kymera Therapeutics (KYMR) trades as ordinary local shares, while Novartis (NVS) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Kymera Therapeutics (KYMR) has an aggressive beta of 2.00, indicating higher sensitivity to broad-market moves, while Novartis (NVS) is defensive at 0.41 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Kymera Therapeutics (KYMR) reports a negative ROE of -27.29%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Novartis (NVS) reports 24.33%, ranking against industry peers normally.

Novartis (NVS) at 17.49% retains a top-quartile share of revenue as profit, ahead of Kymera Therapeutics (KYMR) at 0.00%, which keeps about the industry-typical share.

Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Novartis (NVS) reports 34.27%, ranking against industry peers normally.

Profitability Metrics

Growth

Novartis (NVS) at 9.57% is around its peer norm for revenue growth, while Kymera Therapeutics (KYMR) at -16.70% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: Novartis (NVS) reports EPS growth of 21.81%, ranked against its industry; Kymera Therapeutics (KYMR) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Kymera Therapeutics (KYMR) at 11.13 keeps current ratio within its industry’s typical mid-range, while Novartis (NVS) at 0.88 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NVS.

Kymera Therapeutics (KYMR) at 0.05 carries an industry-typical debt-to-equity mix, while Novartis (NVS) at 1.29 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Kymera Therapeutics (KYMR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novartis (NVS) reports a yield of 2.88%, ranking against industry peers normally.

Kymera Therapeutics (KYMR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novartis (NVS) reports a payout of 90.46%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Novartis (NVS) trades at 31.02 times trailing earnings, ranked against its peers, while Kymera Therapeutics (KYMR) has no P/E ratio this period.

Novartis (NVS) at 5.35 prices around its industry’s typical P/S ratio, while Kymera Therapeutics (KYMR) at 110.00 clears its benchmark range — KYMR looks notably rich on sales.

Both Kymera Therapeutics (KYMR) at 6.96 and Novartis (NVS) at 8.25 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

Valuation Metrics